NEW YORK (dpa-AFX) - The Canadian bank RBC has lowered its price target for Carl Zeiss Meditec from 145 to 85 euros, but left its rating at "Outperform". Analyst Jack Reynolds-Clark adjusted his forecasts for the medical technology company to its reduced annual targets. However, the low visibility of the short-term sales development belies the underlying strength and robust market shares, he wrote in a study published on Monday. He continues to see significant longer-term upside potential and the current multi-year low of the share as a buying opportunity./edh/mis

Publication of the original study: 23.06.2024 / 17:33 / EDT

First dissemination of the original study: 24.06.2024 / 00:45 / EDT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------